BackPrestige BioPharma Limited Overview

Prestige BioPharma Limited EBIT

Latest ebit for 950210.KS: $-94B, below the Healthcare sector average of $1.1T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$23.25B
↓ 339.57% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$93.56B
↓ 252.77% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Prestige BioPharma Limited (950210.KS) FAQ

Prestige BioPharma Limited (950210.KS) currently reports a EBIT of $-94B as of June 2026. That compares with $-27B in the prior-year period — down 252.8% year over year. That is below the Healthcare sector average of $1.1T. Use the charts on this page to explore Prestige BioPharma Limited's EBIT history and peer comparisons.

Prestige BioPharma Limited's EBIT decreased from $-27B to $-94B — a 252.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Prestige BioPharma Limited's EBIT of $-94B is lower than the Healthcare sector average of $1.1T. That is roughly 108.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Prestige BioPharma Limited reported $-94B in EBIT as of June 2026. That compares with $-27B in the prior-year period — down 252.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-94B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.1T. From there, open related valuation or income-statement pages for Prestige BioPharma Limited, and consider following 950210.KS for alerts when major investors trade the stock.

Questions & Answers